You are here

Home » Content

Kronik Böbrek Yetmezliği Olan Bir Olguda Pansitopeni Nedeni: Hodgkin Lenfoma

Cause of Pancytopenia in a Case With Chronic Renal Failure: Hodgkin's Lymphoma

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Hodgkin's lymphoma is a malign disease of lmyphatic system. It's known that, chronic renal failure may occur as a result of glomerular pathology which develops due to malign diseases. But, association of Hodgkin's lymphoma is not frequently observed in patients who have chronic renal failure and undergo hemodialysis. Pancytopenia was detected after laboratory examination of the patient who had been undergoing hemodialysis for six years. Cause of pancytopenia was searched and Hodgkin's lymphoma was diagnosed. In the overview of the literature, it was seen that, association of lymphoma in patients with chronic renal failure is rare.
Bookmark/Search this post with
Abstract (Original Language): 
Hodgkin lenfoma lenfoid sistemin malign bir hastalığıdır. Malign hastalıklara bağlı olarak gelişen glomerüler patolojiler sonucunda kronik böbrek yetmezliği oluşabileceği bilinmektedir. Ancak kronik böbrek yetmezliği olan ve hemodiyaliz tedavisi gören hastalarda Hodgkin lenfoma birlikteliğinin sık olmadığı gözlenmiştir. Altı yıldır hemodiyaliz tedavisi gören hastanın yapılan tetkikler sonucunda pansitopenisi tespit edildi. Pansitopeninin nedeni araştırıldı ve Hodgkin lenfoma tanısı konuldu. Literatür incelemesinde, kronik böbrek yetmezliği tanısı olan hastalarda lenfoma birlikteliğinin na¬ dir olduğu görüldü.
FULL TEXT (PDF): 
PDF icon pdf_tndt_518.pdf
  • 1
45-47
  • Turkish

REFERENCES

References: 

1. Mowry JE, Nissenson AR. Anemia. In: Massry SG, Glassock RJ (Eds), Textbook of Nephrology. Williams and Wilkins, Baltimore 1996, pp 1368-1373.
2. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease, 2000. Am J Kidney Dis 2001;37:S182-S238 (suppl 1).
3. Skorecki K, Green J, Brenner BM. Chronic renal failure. In: Braunwald E, Fauci AS, Kasper DL, et al (Eds), Harrison's Principles of Internal Medicine. McGraw-Hill Co, London 2001, pp 1551-1561.
4. Altieri P, Sau G, Cao R, et al. Immunsupressive treatment in di¬alysis patients. Nephrol Dial Transplant 2002;17(suppl 8):2-9.
5. Williams DM. Pancytopenia, aplastic anemia and pure red
cell aplasia. In: Lee GR, Foerster J, Lukens J, Bithell TC, At¬hens JW (Eds). Wintrobe's Clinical Hematology. Mass Publis¬hing Co, Pennsylvania 1993, pp 911-937.
6. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-di-agnosis and treatment. Lancet Oncol 2004 Jan;5(1):19-26.
7. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lympho-
ma-molecular biology of Hodgkin and Reed-Sternbergcells. Lancet Oncol 2004 Jan;5(1):11-8.
8. Maesaka J, Mittel S, Fishbane S. Paraneoplastic syndromes of
the kidney. Semin Oncol 1997;24(3):373-81.
9. Ambinder R. Infection and lymphoma. N Engl J Med 2003 Oct 2;349(14):1309-11.
10. Gupta T, Sanghavi V, Laskar S. Radiotherapy for advanced
Hodgkin's disease. N Engl J Med 2003 Sep 18;349(12):1187-8.
11. Ekert H. Chemotherapy for Hodgkin's disease. N Engl J Med
2003 Sep 18;349(12):1186-7.
12. Mellotte G, Gaffney EF, Keogh JA. Thrombotic microangi-opathy and renal failure as the initial manifestation of Hodg-kin's disease. Nephrol Dial Transplant 1993;8(1):94-5.

Thank you for copying data from http://www.arastirmax.com